<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> remains a major source of morbidity and mortality in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This article examines the recent evidence from trials and related meta-analyses on the effects of glycaemic control on <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (and, to a lesser extent, microvascular outcomes) in <z:mp ids='MP_0002055'>diabetes</z:mp>, and compares this with evidence accrued from blood pressure and <z:chebi fb="0" ids="35664">statin</z:chebi> trials </plain></SENT>
<SENT sid="2" pm="."><plain>On the basis of such evidence, as well as pragmatic considerations, it is clear that clinicians should place stronger emphasis on <z:chebi fb="23" ids="18059">lipid</z:chebi> and blood pressure management to lessen cardiovascular risks </plain></SENT>
<SENT sid="3" pm="."><plain>At the same time, <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> benefits of glycaemia reduction appear less pronounced, with patient characteristics critically influencing risk to benefit ratio </plain></SENT>
<SENT sid="4" pm="."><plain>Recent guidelines now reflect recent observations on glycaemic control (with relaxed targets in specific patient groups), whereas future guidelines should encourage physicians to prioritize <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering and blood pressure management in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>